MWNA
AKBA icon

Marshall Wace North America’s Akebia Therapeutics AKBA Stock Holding History

Marshall Wace North America’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-431,862
Closed -$5.86M – 1182
2020
Q2 		$5.86M Buy
+431,862
New +$4.47M 0.04% 349
2019
Q1 		– Sell
-22,477
Closed -$124K – 1525
2018
Q4 		$124K Sell
22,477
-558,072
-96% -$4.37M ﹤0.01% 1042
2018
Q3 		$5.13M Hold
580,549
– – 0.04% 313
2018
Q2 		$5.79M Sell
580,549
-17,738
-3% -$178K 0.03% 476
2018
Q1 		$5.7M Sell
598,287
-5,527
-0.9% -$77.3K 0.03% 540
2017
Q4 		$8.98M Buy
603,814
+114,913
+24% +$1.91M 0.05% 408
2017
Q3 		$9.78M Buy
488,901
+99,131
+25% +$1.52M 0.06% 368
2017
Q2 		$5.46M Sell
389,770
-302,726
-44% -$3.84M 0.04% 474
2017
Q1 		$6.23M Buy
+692,496
New +$6.76M 0.05% 349

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace North America's AKBA Position: Q3 2020 in Review

Marshall Wace North America sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 431,862 shares — an estimated $5.86M sold.

Marshall Wace North America first reported a position in AKBA in Q1 2017 and held it in 9 quarters. The position peaked at $9.78M in Q3 2017. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Marshall Wace North America reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 431,862 Akebia Therapeutics shares in Q3 2020, an estimated $5.86M.
  • Marshall Wace North America first reported a position in Akebia Therapeutics in Q1 2017 and held it in 9 quarters.
  • Marshall Wace North America's Akebia Therapeutics position peaked at $9.78M in Q3 2017.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.